Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01149499 · ClinicalTrials.gov registry record · Phase 1

Valacyclovir 1000 mg Tablet Under Fasting Conditions

A Phase 1 study of Healthy, sponsored by Teva Pharmaceuticals U.

Completed
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT01149499 is a Phase 1 study of Healthy that has completed, run by Teva Pharmaceuticals U. The registered enrollment target is 60 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01149499, a Phase 1 study of Healthy, has completed, sponsored by Teva Pharmaceuticals U.

COMPLETED
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to compare the rate and extent of absorption of valacyclovir 1000 mg tablet (test) versus Valtrex (reference), administered as 1 x 1000 mg tablet under fasting conditions.

Conditions Studied

Interventions

  • DRUG Valacyclovir

Study Locations (1)

Minnesota

  • PRACS Institute, Ltd. - East Grand Forks

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2005-01
Est. Completion 2005-01
Phase Phase 1

Sponsor

Teva Pharmaceuticals U

19 total trials

What the Registry Record Tells You About NCT01149499

The ClinicalTrials.gov registry entry for NCT01149499 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The listed sponsor is Teva Pharmaceuticals U, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Valacyclovir is the first listed.

NCT01149499 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT01149499 about?

NCT01149499 is a clinical study titled "Valacyclovir 1000 mg Tablet Under Fasting Conditions". The objective of this study is to compare the rate and extent of absorption of valacyclovir 1000 mg tablet (test) versus Valtrex (reference), administered as 1 x 1000 mg tablet under fasting conditions.

What is the current status of trial NCT01149499?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2005-01. Estimated completion is 2005-01.

What conditions does trial NCT01149499 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01149499?

The interventions under investigation include: Valacyclovir (DRUG).

Who is sponsoring clinical trial NCT01149499?

This trial is sponsored by Teva Pharmaceuticals U, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01149499 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.